Advances in the treatment of RET-fusion-positive lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• RET-fusions identified as oncogenic drivers in ~1% of metastatic lung adenocarcinomas a decade ago.
• Early multikinase inhibitors showed limited antitumor activity in clinical trials.
• Recent development of selective RET-inhibitors marks a significant advancement.

Purpose of the Study:

• To review the efficacy and application of newly approved RET-inhibitors.
• To discuss the management strategies for patients with RET-fusion-positive non-small cell lung cancer (RET-NSCLC).
• To highlight the therapeutic progress in treating RET-altered lung cancers.

Main Methods:

• Literature review of clinical trials and research on RET-inhibitors.
• Discussion of the mechanism of action for selpercatinib and pralsetinib.
• Analysis of patient management guidelines for RET-NSCLC.

Main Results:

• Two selective and potent RET-inhibitors, selpercatinib and pralsetinib, have been approved.
• These agents demonstrate significant promise in treating RET-fusion-positive NSCLC.
• Improved therapeutic options are now available for this patient population.

Conclusions:

• Selpercatinib and pralsetinib represent a breakthrough in targeted therapy for RET-NSCLC.
• Effective management of RET-NSCLC involves utilizing these selective inhibitors.
• Ongoing research continues to refine treatment approaches for RET-fusion-positive lung cancer.